IDEXX Laboratories, Inc.
IDEXX Laboratories, Inc. Q2 FY26 Results — Earnings Call Analysis
Q2 FY26 earnings call: what management said on revenue, margins and capex.
What the Q2 FY26 call signalled
2 of 3 strong
The short version
- Full-year 2026 revenue outlook increased to $4.675B-$4.76B, reflecting a $32M constant currency improvement on strong Q1 results. - Full year 2026 revenue guidance increased to $4.675 billion to $4.76 billion, up $42 million at midpoint.
From IDEXX Laboratories, Inc.'s Q2 FY26 earnings-call transcript · updated 29 May 2026.
Revenue & Sales Performance
- Full-year 2026 revenue outlook increased to $4.675B-$4.76B, reflecting a $32M constant currency improvement on strong Q1 results.
- Organic revenue growth projected at 7.7%-9.7%, with CAG Diagnostics recurring revenue growth at 8.7%-10.7%, driven by volume gains and ~4% net price realization.
- Instrument placements for inVue Dx expected to reach 5,500 in 2026, with strong commercial execution and widening adoption of innovations (e.g., Cancer DX, F&A launch ramping in 2H).
- Clinical visits expected to decline modestly (-1.5% in U.S.) but offset by expanding diagnostic frequency and utilization per visit.
- International markets anticipated for continued double-digit growth due to long-term investments, innovation, and commercial expansion.
- Positive momentum seen from aging pet population driving increased visits and diagnostic usage.
2 more points from IDEXX Laboratories, Inc.'s call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what IDEXX Laboratories, Inc. said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Full year capital spending forecasted at approximately $180 million for 2026.
- Investments focused on advancing global commercial and innovation capabilities.
- Continued expansion of field-based presence in key geographies to support commercial reach.
- Investments in innovation-driven platform growth strategy, including diagnostics and software.
- Development of AI capabilities embedded in platforms like inVue Dx and ezyVet, with more advancements planned.
- Growing cloud-native software offerings and diagnostic platforms such as Cancer DX and inVue Dx.
2 more points from IDEXX Laboratories, Inc.'s call on capex
Create a free account to keep reading this call
Fundraising & Capital Structure
See what IDEXX Laboratories, Inc. said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
See what IDEXX Laboratories, Inc. said on order book & pipeline — free account, 30 seconds.
Continue your research
Others in Health Care Equipment and Supplies this season
- Insulet Corporation (Q2 FY26)
Insulet Corporation Q2 FY26 quarterly results analysis. Full year 2026 total company revenue growth guidance raised to 21%-23%; Omnipod revenue growth of 22%-24
- Globus Medical, Inc. (Q2 FY26)
Globus Medical, Inc. Q2 FY26 quarterly results analysis. U.S. Market Cap $11,192, P/E 19.9. AI-powered earnings insights.
- Align Technology, Inc. (Q2 FY26)
Align Technology, Inc. Q2 FY26 quarterly results analysis. Worldwide revenue growth for full-year 2026 is expected to be up 3% to 4% year-over-year. Market Cap
- Solventum Corporation (Q2 FY26)
Solventum Corporation Q2 FY26 quarterly results analysis. Expectation of improved growth in 2026 compared to 2025, supporting trajectory toward LRP targets (Pag
Potential multibaggers · Q2 FY27
This quarter's potential multibaggers
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
IDEXX Laboratories, Inc. and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were IDEXX Laboratories, Inc. Q2 FY26 results?
- Full-year 2026 revenue outlook increased to $4.675B-$4.76B, reflecting a $32M constant currency improvement on strong Q1 results. - Full year 2026 revenue guidance increased to $4.675 billion to $4.76 billion, up $42 million at midpoint.
What is IDEXX Laboratories, Inc. share price analysis?
IDEXX Laboratories, Inc. currently shows a below-average growth signal. The stock trades at a P/E of 41.0 with a market cap of $44,808. Investors should review the full earnings analysis for detailed insights.
Is IDEXX Laboratories, Inc. planning capital expenditure?
- Full year capital spending forecasted at approximately $180 million for 2026.
Keep IDEXX Laboratories, Inc. on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.